No Data
Boji Medical Technology (300404.SZ): Obtained 1 invention patent certificate.
Gelonghui, March 24 - Boji Medical Technology (300404.SZ) announced that recently, Boji Medical Technology Co., Ltd. has obtained an invention patent certificate issued by the National Intellectual Property Administration for a method of preparing sodium loxoprofen gel patches.
Boji Medical Technology Sells Rights to Glucosamine Sulfate Capsules for 4.5 Million Yuan
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Boji Medical Technology (300404.SZ): has obtained an invention patent certificate.
Gelonghui, March 14th丨Boji Medical Technology (300404.SZ) announced that recently, Boji Medical Technology Co., Ltd. received an invention patent certificate issued by the National Intellectual Property Office for the preparation method of Hydroxy Safflower Yellow A.
Investors Continue Waiting On Sidelines For Boji Medical Technology Co.,Ltd. (SZSE:300404)
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Market Cool On Boji Medical Technology Co., Ltd.'s (SZSE:300404) Revenues Pushing Shares 25% Lower
